Compare KNTK & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNTK | IRON |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2017 | 2020 |
| Metric | KNTK | IRON |
|---|---|---|
| Price | $51.29 | $64.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $57.31 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 963.3K | 444.2K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 6.45% | N/A |
| EPS Growth | ★ 157.84 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $160,617,000.00 | N/A |
| Revenue This Year | $16.68 | N/A |
| Revenue Next Year | $14.16 | N/A |
| P/E Ratio | $84.11 | ★ N/A |
| Revenue Growth | ★ 8.23 | N/A |
| 52 Week Low | $31.33 | $40.00 |
| 52 Week High | $56.92 | $99.50 |
| Indicator | KNTK | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 30.31 | 31.11 |
| Support Level | $44.64 | $65.04 |
| Resistance Level | $51.72 | $72.68 |
| Average True Range (ATR) | 1.42 | 2.42 |
| MACD | -0.51 | -0.21 |
| Stochastic Oscillator | 12.12 | 22.75 |
Kinetik Holdings Inc is a midstream operator that provides comprehensive gathering, transportation, compression, processing and treating services. Its activities also include NGL stabilization and transportation, produced water gathering and disposal, and crude oil gathering, stabilization, storage, and transportation. The company operates in two reportable segments: i) The Midstream Logistics segment operates under three service offerings: 1) gas gathering and processing, 2) crude oil gathering, stabilization, and storage services, and 3) produced water gathering and disposal. ii) The Pipeline Transportation segment consists of two EMI Pipelines originating in the Permian Basin with various access points to the U.S. Gulf Coast, Kinetik NGL Pipelines, and Delaware Link Pipeline.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.